TW200716094A - Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor - Google Patents
Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitorInfo
- Publication number
- TW200716094A TW200716094A TW095114529A TW95114529A TW200716094A TW 200716094 A TW200716094 A TW 200716094A TW 095114529 A TW095114529 A TW 095114529A TW 95114529 A TW95114529 A TW 95114529A TW 200716094 A TW200716094 A TW 200716094A
- Authority
- TW
- Taiwan
- Prior art keywords
- methods
- pharmaceutical compositions
- aromatase inhibitor
- combination
- phenyl
- Prior art date
Links
- 229940122815 Aromatase inhibitor Drugs 0.000 title abstract 3
- 239000003886 aromatase inhibitor Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229940095743 selective estrogen receptor modulator Drugs 0.000 title 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 abstract 1
- GGPPBTSXFROGAE-UHFFFAOYSA-N 4-[(4-bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile Chemical compound C1=CC(Br)=CC=C1CN(N1C=NN=C1)C1=CC=C(C#N)C=C1 GGPPBTSXFROGAE-UHFFFAOYSA-N 0.000 abstract 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 abstract 1
- 229960003437 aminoglutethimide Drugs 0.000 abstract 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 abstract 1
- 229960002932 anastrozole Drugs 0.000 abstract 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 abstract 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 abstract 1
- 229950004810 atamestane Drugs 0.000 abstract 1
- 229960000255 exemestane Drugs 0.000 abstract 1
- 229950011548 fadrozole Drugs 0.000 abstract 1
- SLJZVZKQYSKYNV-ZWKOTPCHSA-N finrozole Chemical compound C([C@H](O)[C@@H](C=1C=CC(=CC=1)C#N)N1N=CN=C1)C1=CC=C(F)C=C1 SLJZVZKQYSKYNV-ZWKOTPCHSA-N 0.000 abstract 1
- 229950001083 finrozole Drugs 0.000 abstract 1
- 229960004421 formestane Drugs 0.000 abstract 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 abstract 1
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 abstract 1
- 229960003881 letrozole Drugs 0.000 abstract 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 abstract 1
- 229960001771 vorozole Drugs 0.000 abstract 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof a combination of a 2-(-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5, 6, 7, 8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt or prodrug thereof and an aromatase inhibitor. Particularly, the present invention relates to pharmaceutical compositions and methods of treatment comprising administering to a patient in need thereof (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt or prodrug and an aromatase inhibitor selected from aminoglutethimide; formestane; atamestane; anastrazole; fadrozole; finrozole; letrozole; vorozole; 4-[N-(4-bromobenzyl)-N-(4-cyanophenyl)amino]-4H-1,2,4-triazole or exemestane, or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67480705P | 2005-04-25 | 2005-04-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200716094A true TW200716094A (en) | 2007-05-01 |
Family
ID=36693972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095114529A TW200716094A (en) | 2005-04-25 | 2006-04-24 | Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1937251A2 (en) |
| JP (1) | JP2006306872A (en) |
| AR (1) | AR054258A1 (en) |
| CA (1) | CA2605796A1 (en) |
| TW (1) | TW200716094A (en) |
| WO (1) | WO2006114702A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090029237A (en) | 2006-06-02 | 2009-03-20 | 피어 트리 파머슈티칼스 인코포레이티드 | How to treat atrophic vaginitis |
| EP2070943A1 (en) * | 2007-12-14 | 2009-06-17 | Crystal Pharma, S.A. | Process for obtaining 6-Alkylidenandrost-1,4-diene-3one |
| JP5777163B2 (en) * | 2009-07-03 | 2015-09-09 | 国立研究開発法人理化学研究所 | Labeling compound for PET |
| JP6280501B2 (en) * | 2011-09-08 | 2018-02-14 | メレオ バイオファーマ ２ リミテッド | Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases |
| CA3022377A1 (en) | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Targeted measure of transcriptional activity related to hormone receptors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552412A (en) * | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
| AR034142A1 (en) * | 2000-09-08 | 2004-02-04 | Sloan Kettering Inst Cancer | A PHARMACEUTICAL COMPOSITION, METHOD FOR MANUFACTURING A MEDICINAL BASED ON SUCH COMPOSITION AND USE OF THE COMPOSITION |
| EP1317270A1 (en) * | 2000-09-08 | 2003-06-11 | Pharmacia Italia S.p.A. | Exemestane for the treatment of oestrogen-dependent cancers |
| WO2003017973A1 (en) * | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method |
| EP1435967A2 (en) * | 2001-10-10 | 2004-07-14 | Pharmacia Italia S.p.A. | Methods for preventing and treating bone loss with steroid compounds |
| TW200526206A (en) * | 2004-01-13 | 2005-08-16 | Wyeth Corp | Treatment of aromatase inhibitor therapy-related osteoporosis |
| CA2586844A1 (en) * | 2004-11-04 | 2006-05-11 | Pfizer Products Inc. | Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
-
2006
- 2006-04-13 EP EP06744583A patent/EP1937251A2/en not_active Withdrawn
- 2006-04-13 WO PCT/IB2006/001040 patent/WO2006114702A2/en not_active Ceased
- 2006-04-13 CA CA002605796A patent/CA2605796A1/en not_active Abandoned
- 2006-04-24 AR AR20060101616A patent/AR054258A1/en not_active Application Discontinuation
- 2006-04-24 JP JP2006118713A patent/JP2006306872A/en active Pending
- 2006-04-24 TW TW095114529A patent/TW200716094A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR054258A1 (en) | 2007-06-13 |
| CA2605796A1 (en) | 2006-11-02 |
| WO2006114702A2 (en) | 2006-11-02 |
| EP1937251A2 (en) | 2008-07-02 |
| JP2006306872A (en) | 2006-11-09 |
| WO2006114702A3 (en) | 2007-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE504565T1 (en) | AZETIDINES AS MEK INHIBITORS IN THE TREATMENT OF PROLIFERATIVE DISEASES | |
| JP2010521483A5 (en) | ||
| CY1109860T1 (en) | FACTORS OF HISTAMIN H3 CONTAINERS, PREPARATION AND THERAPEUTIC USES | |
| GEP20115213B (en) | Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists | |
| NZ593593A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| TW200626148A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| PH12021551290A1 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| TW200626138A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| TW200626139A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| ATE371656T1 (en) | HETEROARYL-PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | |
| TW200626592A (en) | Heterocyclic derivatives and their use as therapeutic agents | |
| EE200300403A (en) | N-substituted Non-Aromatic Heterocyclic Compound, Pharmaceutical Composition Containing It, and Use of the Compound as a Pharmaceutical | |
| NO20060981L (en) | Pyridazine derivatives and their use as therapeutic agents | |
| UA86957C2 (en) | Azepinoindole derivatives as pharmaceutical agents | |
| UA84146C2 (en) | Amides of pyrrolopyridine-2-carboxylic acid as inhibitors of glycogen phosphorylase, method for their synthesis, drug formulation, and their use as therapeutic agents | |
| RU2009118254A (en) | PHENYLACETAMIDES AS PROTEINKINASE INHIBITORS | |
| CA2484188A1 (en) | Tachykinin receptor antagonists | |
| NO20070224L (en) | 2-urea-4-phenylthiazole derivatives, preparation and therapeutic use thereof | |
| NO20054905L (en) | 2-acylamino-4-phenylthiazole derivatives, methods for their preparation and use of the same as in therapeutics | |
| CA2409741A1 (en) | Tnf-.alpha. production inhibitors | |
| NO20081844L (en) | Therapeutic compounds | |
| ATE384058T1 (en) | THIAZOLE DERIVATIVES | |
| NO20056192L (en) | Capase inhibitors and their use | |
| WO2005030187A3 (en) | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension | |
| MXPA06003122A (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist. |